RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oramed Pharmaceuticals Stock

Oramed Pharmaceuticals Net Income 2024

Oramed Pharmaceuticals Net Income

4.37 M USD

Ticker

ORMP

ISIN

US68403P2039

WKN

A1CTNU

In 2024, Oramed Pharmaceuticals's profit amounted to 4.37 M USD, a -20.97% increase from the 5.53 M USD profit recorded in the previous year.

The Oramed Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2028e-30.36
2027e-34.1
2026e-52.4
2025e-5.41
2024e4.37
20235.53
2022-36.56
2021-11.67
2020-22.24
2019-11.51
2018-14.36
2017-12.73
2016-10.48
2015-10.96
2014-7.23
2013-5.7
2012-4.23
2011-3.34
2010-1.56
2009-2.98
2008-2.76
2007-2.77
2006-3.24
2005-0.42
2004-0.05

Oramed Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oramed Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oramed Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oramed Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oramed Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oramed Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oramed Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oramed Pharmaceuticals’s growth potential.

Oramed Pharmaceuticals Revenue, EBIT and net profit per share

DateOramed Pharmaceuticals RevenueOramed Pharmaceuticals EBITOramed Pharmaceuticals Net Income
2028e0 undefined-54.88 M undefined-30.36 M undefined
2027e0 undefined-53.65 M undefined-34.1 M undefined
2026e0 undefined-52.53 M undefined-52.4 M undefined
2025e2.04 M undefined-26.52 M undefined-5.41 M undefined
2024e765,000 undefined-15.94 M undefined4.37 M undefined
20231.34 M undefined-15.77 M undefined5.53 M undefined
20222.7 M undefined-40.6 M undefined-36.56 M undefined
2021904,000 undefined-12.33 M undefined-11.67 M undefined
20202.7 M undefined-24.22 M undefined-22.24 M undefined
20192.71 M undefined-11.76 M undefined-11.51 M undefined
20182.7 M undefined-14.63 M undefined-14.36 M undefined
20172.45 M undefined-13.53 M undefined-12.73 M undefined
20162.46 M undefined-10.77 M undefined-10.48 M undefined
2015640,000 undefined-10.01 M undefined-10.96 M undefined
20140 undefined-7.38 M undefined-7.23 M undefined
20130 undefined-5.91 M undefined-5.7 M undefined
20120 undefined-4.3 M undefined-4.23 M undefined
20110 undefined-2.89 M undefined-3.34 M undefined
20100 undefined-2.43 M undefined-1.56 M undefined
20090 undefined-2.97 M undefined-2.98 M undefined
20080 undefined-2.78 M undefined-2.76 M undefined
20070 undefined-2.68 M undefined-2.77 M undefined
20060 undefined-3.13 M undefined-3.24 M undefined
20050 undefined-410,000 undefined-420,000 undefined
20040 undefined-50,000 undefined-50,000 undefined

Oramed Pharmaceuticals stock margins

The Oramed Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oramed Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oramed Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oramed Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Oramed Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oramed Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oramed Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oramed Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oramed Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oramed Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oramed Pharmaceuticals Margin History

Oramed Pharmaceuticals Gross marginOramed Pharmaceuticals Profit marginOramed Pharmaceuticals EBIT marginOramed Pharmaceuticals Profit margin
2028e100 %0 %0 %
2027e100 %0 %0 %
2026e100 %0 %0 %
2025e100 %-1,300 %-265 %
2024e100 %-2,084.13 %570.78 %
2023100 %-1,176.79 %412.31 %
2022100 %-1,503.7 %-1,354.07 %
2021100 %-1,363.5 %-1,290.71 %
2020100 %-897.04 %-823.7 %
2019100 %-433.95 %-424.72 %
201896.67 %-541.85 %-531.85 %
2017103.67 %-552.24 %-519.59 %
201692.28 %-437.8 %-426.02 %
201523.44 %-1,564.06 %-1,712.5 %
2014100 %0 %0 %
2013100 %0 %0 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %

Oramed Pharmaceuticals Aktienanalyse

What does Oramed Pharmaceuticals do?

Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Oramed Pharmaceuticals's Profit Margins

The profit margins of Oramed Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Oramed Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Oramed Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Oramed Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Oramed Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Oramed Pharmaceuticals stock

How much profit has Oramed Pharmaceuticals made this year?

Oramed Pharmaceuticals has made 4.37 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -20.97% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Oramed Pharmaceuticals publish its earnings?

Oramed Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Oramed Pharmaceuticals?

The profits of Oramed Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Oramed Pharmaceuticals?

You can learn more about the earnings of Oramed Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Oramed Pharmaceuticals pay?

Over the past 12 months, Oramed Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oramed Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Oramed Pharmaceuticals?

The current dividend yield of Oramed Pharmaceuticals is .

When does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oramed Pharmaceuticals?

Oramed Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Oramed Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oramed Pharmaceuticals located?

Oramed Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oramed Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oramed Pharmaceuticals from 9/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Oramed Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Oramed Pharmaceuticals in the year 2023?

In the year 2023, Oramed Pharmaceuticals distributed 0 USD as dividends.

In which currency does Oramed Pharmaceuticals pay out the dividend?

The dividends of Oramed Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oramed Pharmaceuticals

Our stock analysis for Oramed Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oramed Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.